Your Health, We Care
In July 2023, Lao Lucius Pharmaceutical obtained approval from the Lao government and received the Drug Registration Certificate (Production Approval) for Capmatinib (Lucicapma). In the same month, it also obtained the Drug Analysis Test Report.
Registration No.: 07 L 0996/23
Inspection No.: 1765-23
On February 11, 2020, Novartis announced that the U.S. Food and Drug Administrat···【more】
Release date：2026-01-09Recommended：279
On May 6, 2020, Novartis announced today that the U.S. Food and Drug Administrat···【more】
Release date：2026-01-09Recommended：298
Capmatinib inhibits the proliferation and survival of MET-dependent cancer cells···【more】
Release date：2024-08-07Recommended：410
Capmatinib is highly selective for c-Met targets, can effectively inhibit the pr···【more】
Release date：2024-08-07Recommended：451
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or t···【more】
Release date：2024-08-06Recommended：477
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
